Vascular surgery

Varicose Vein Treatment Market Soaring at 5.7% CAGR to Register $589.06 Million by 2025

Retrieved on: 
Wednesday, April 24, 2019

Varicose vein is harmful to health if they lead to venous stasis ulcers, phlebitis, thrombosis, venous hemorrhage, or fungal and bacterial infections.

Key Points: 
  • Varicose vein is harmful to health if they lead to venous stasis ulcers, phlebitis, thrombosis, venous hemorrhage, or fungal and bacterial infections.
  • Request a Sample Copy of this Research Report: https://www.bigmarketresearch.com/request-sample/2955690
    Considerable rise in prevalence of varicose vein problem, surge in geriatric population, advanced varicose vein treatment devices, engagement in occupation that increases the prevalence of varicose vein treatment and technological advancements globally, boost the growth of the market.
  • Whereas, increase in level of awareness as well as development in the emerging markets create numerous opportunities in the varicose vein treatment market.
  • The global varicose vein treatment market is segmented based on procedure, product, end user, and region.

Worldwide Hemodialysis Vascular Grafts Industry Study 2019

Retrieved on: 
Wednesday, April 24, 2019

The global hemodialysis vascular grafts market is expected to reach from US$ 196.6 Mn in 2017 to US$ 285.2 Mn by 2026 expanding at a CAGR of 4.3% from 2018 to 2026.

Key Points: 
  • The global hemodialysis vascular grafts market is expected to reach from US$ 196.6 Mn in 2017 to US$ 285.2 Mn by 2026 expanding at a CAGR of 4.3% from 2018 to 2026.
  • Polytetrafluoroethylene currently dominates the raw material segment for hemodialysis vascular grafts market.
  • With a market share of 36%, North America is the largest regional market in hemodialysis vascular grafts market.
  • Pharmaceutical companies manufacturing hemodialysis vascular grafts are C.R.Bard, Inc., CryoLife, Inc., Getinge AB., InnAVasc Medical, Inc., LeMaitre Vascular, Inc., Merit Medical Systems, Inc., Proteon Therapeutics, Inc., Terumo Medical Corporation, Vascular Genesis and W.L.Gore Associates.

Vascular Grafts Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026

Retrieved on: 
Monday, April 22, 2019

The global vascular grafts market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market.It also provides information and data analysis of the global market with respect to the segments based on product, source, size of vascular grafts, application, end-user, and region.

Key Points: 
  • The global vascular grafts market report comprises an elaborate executive summary, which includes a snapshot that provides information about various segments of the market.It also provides information and data analysis of the global market with respect to the segments based on product, source, size of vascular grafts, application, end-user, and region.
  • In terms of product, the global vascular grafts market has been segmented into endovascular stent grafts, peripheral vascular grafts, hemodialysis access grafts, bypass grafts, and others.In terms of source, the market has been classified into synthetic, biological, and biosynthetic.
  • The biosynthetic segment has been bifurcated into ovine collagen with polyester and others.In terms of size of vascular grafts, the global vascular grafts market has been classified into large and small.
  • Based on end-user, the global vascular grafts market has been divided into hospitals, ambulatory surgery centers, cardiac catheterization laboratories, specialty clinics, and others.

What vascular surgeons wish patients knew about their circulation

Retrieved on: 
Monday, April 22, 2019

Here are a few basics that vascular specialists wish patients knew:

Key Points: 
  • Here are a few basics that vascular specialists wish patients knew:
    1.
  • While part of vascular disease is the result of aging or disease, everyone's vascular health benefits from maintaining good habits.
  • Not all vascular conditions require surgery, however, and many patients only need physical therapy or medication.
  • The Society for Vascular Surgery (SVS) is a not-for-profit professional medical society, composed of specialty-trained vascular surgeons and professionals, which seeks to advance excellence and innovation in vascular health through education, advocacy, research and public awareness.

NueHealth Facility CSA Surgical Center Receives Quality Improvement Award

Retrieved on: 
Friday, April 19, 2019

LEAWOOD, Kan., April 19, 2019 /PRNewswire/ -- CSA Surgical Center (CSASC), a NueHealth partnership with a group of highly-qualified General and Vascular Surgeons from Columbia Surgical Associates in Columbia, MO, received the Bernard A. Kershner Innovations in Quality Improvement Award (Surgical/Procedural Expert Panel) on March 15 at the AAAHC Achieving Accreditation program in Tampa, Florida.

Key Points: 
  • LEAWOOD, Kan., April 19, 2019 /PRNewswire/ -- CSA Surgical Center (CSASC), a NueHealth partnership with a group of highly-qualified General and Vascular Surgeons from Columbia Surgical Associates in Columbia, MO, received the Bernard A. Kershner Innovations in Quality Improvement Award (Surgical/Procedural Expert Panel) on March 15 at the AAAHC Achieving Accreditation program in Tampa, Florida.
  • The Bernard A. Kershner Innovations in Quality Improvement Award recognizes exemplary quality improvement studies conducted by AAAHC-accredited facilities.
  • Reduced post-op pain also means a reduced hospital or facility stay for the patient, making the approach both cost-effective and a quality of life improvement for patients.
  • CSA Surgical Center is a ambulatory surgical center in Columbia, Missouri performing general and vascular surgery procedures.

CryoLife Announces Release Date and Teleconference Call Details for 2019 First Quarter Financial Results

Retrieved on: 
Wednesday, April 17, 2019

ATLANTA, April 17, 2019 /PRNewswire/ --CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced todaythat 2019 first quarter financial resultswill be released on Tuesday, April 30, 2019 after the market closes.

Key Points: 
  • ATLANTA, April 17, 2019 /PRNewswire/ --CryoLife, Inc. (NYSE: CRY), a leading cardiac and vascular surgery company focused on aortic disease, announced todaythat 2019 first quarter financial resultswill be released on Tuesday, April 30, 2019 after the market closes.
  • On that day, the Company will hold a teleconference call and live webcast at 4:30 p.m.
  • A replay of the teleconference will be available April 30 through May 7 and can be accessed by calling (toll free) 877-660-6853 or 201-612-7415.
  • In addition, a copy of the earnings press release, which will contain financial and statistical information for the completed quarter and full year, can be accessed in the Investor Relations section of the CryoLife website.

Global Peripheral Vascular Devices Industry, 2019 to 2024 - Atherectomy Devices are Expected to Dominate - ResearchAndMarkets.com

Retrieved on: 
Wednesday, April 17, 2019

The "Peripheral Vascular Devices Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Peripheral Vascular Devices Market - Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering.
  • It has affected eight to 12 million people in the United States, especially those over 50 years old.
  • The atherectomy devices segment is expected to dominate the overall market, owing to the increasing prevalence of atherosclerosis, rising obesity, lifestyle-related disorders, and hence the growing adoption.
  • The increasing innovation and rise in investment for various public and private organizations are expected to intensify the industry rivalry across the globe.

Vascular Graft Market to Gain US$3.29 Billion by 2024, Says TMR

Retrieved on: 
Thursday, April 11, 2019

Low reimbursement mechanisms, low-savings, and high-disposal incomes among many are expected to drive growth for the vascular graft market in North America region.

Key Points: 
  • Low reimbursement mechanisms, low-savings, and high-disposal incomes among many are expected to drive growth for the vascular graft market in North America region.
  • Furthermore, conditions such as aneurysm, vascular occlusion, and renal failure are also driving growth for the vascular graft market.
  • The global vascular graft market depicts a competitive and fragmented market, reports Transparency Market Research.
  • In the near future, the vascular graft market players are expected to undertake innovative new strategies and business plans.

Vascular Graft Market to Gain US$3.29 Billion by 2024, Says TMR

Retrieved on: 
Thursday, April 11, 2019

Low reimbursement mechanisms, low-savings, and high-disposal incomes among many are expected to drive growth for the vascular graft market in North America region.

Key Points: 
  • Low reimbursement mechanisms, low-savings, and high-disposal incomes among many are expected to drive growth for the vascular graft market in North America region.
  • Furthermore, conditions such as aneurysm, vascular occlusion, and renal failure are also driving growth for the vascular graft market.
  • The global vascular graft market depicts a competitive and fragmented market, reports Transparency Market Research.
  • In the near future, the vascular graft market players are expected to undertake innovative new strategies and business plans.

Dr. Elsie Koh is First in Greater New York City Area to Pioneer Minimally Invasive Ellipsys Procedure for Dialysis Treatment

Retrieved on: 
Wednesday, April 3, 2019

Interventional radiologist Elsie Koh, MD and her team at Azura Vascular Care have been performing a new vascular procedure using Ellipsys, a new minimally invasive, FDA-approved treatment for patients with kidney failure.

Key Points: 
  • Interventional radiologist Elsie Koh, MD and her team at Azura Vascular Care have been performing a new vascular procedure using Ellipsys, a new minimally invasive, FDA-approved treatment for patients with kidney failure.
  • Dr. Koh is the first doctor to offer Ellipsys to patients in all of New Jersey and the Greater New York City region.
  • Using a percutaneous approach, the Ellipsys procedure replaces an incision with a needle puncture, ultrasound imaging replaces surgical dissection, and sutures are replaced with tissue fusion.
  • Dr. Koh performs the procedure in her same day ambulatory surgical center, but Ellipsys can also be used in hospitals.